



Attorney's Docket No. 047446/273072

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Hardeman et al.	Confirmation No.:	4620
Appl. No.:	10/762,078	Art Unit:	1623
Filed:	January 21, 2004	Examiner:	Not Assigned
For:	ALKYL-LINKED NUCLEOTIDE COMPOSITIONS		

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Kathryn L. Coulter  
Registration No. 45,889

**Customer No. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 15, 2004

  
Nora C. Martinez

Substitute for form 1449A/PTO  
(Revised 10/2001)

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/762,078
Filing Date	January 21, 2004
First Named Inventor	Hardeman et al.
Group Art Unit	1623
Examiner Name	Not Assigned
Attorney Docket Number	047446/273072

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-4,529,796	07-16-1985	Kang et al.	All
	2	US-4,988,680	01-29-1991	Halazy et al.	All
	3	US-5,536,822	07-16-1996	Haystead	All
	4	US-5,650,510	07-22-1997	Webb, II et al.	All
	5	US-5,780,617	07-14-1998	Van den Bosch et al.	All
	6	US-5,854,228	12-29-1998	Webb, II et al.	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	7	EP 0269947 B2	06-08-1988	Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic	All	
	8	EP 0338887 B1	10-25-1999	Merrell Dow Pharmaceuticals, Inc.	All	

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	9	BRESSI, J.C., et al., "Adenosine Analogues as Selective Inhibitors of Glyceraldehyde-3-phosphate Dehydrogenase of <i>Trypanosomatidae</i> via Structure-Based Drug Design," <i>J. Med. Chem.</i> 2001, pp. 2080-2093, Vol. 44	
	10	CHANG, Y.-T., et al., "Synthesis and Application of Functionally Diverse 2,6,9-Trisubstituted Purine Libraries as CDK Inhibitors," <i>Chemistry Biology</i> June 1999; pp. 361-375, Vol. 6, No. 6	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO (Revised 10/2001)				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/762,078
				Filing Date	January 21, 2004
				First Named Inventor	Hardeman et al.
				Group Art Unit	1623
				Examiner Name	Not Assigned
Sheet	2	of	2	Attorney Docket Number	047446/273072

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	11	HALBFINGER, E., et al., "Molecular Recognition of Modified Adenine Nucleotides by the P2Y <sub>1</sub> -Receptor. 1. A Synthetic, Biochemical, and NMR Approach," <i>J. Med. Chem.</i> 1999, pp. 5325-5337, Vol. 42, No. 26	
	12	HERNANDEZ, A-I., et al., "Acyclic Nucleoside Analogues as Novel Inhibitors of Human Mitochondrial Thymidine Kinase," <i>J. Med. Chem.</i> 2002, pp. 4254-4263, Vol. 45, No. 19	
	13	HURYN, D.M., et al., "Synthesis of ISO-DDA, Member of a Novel Class of Anti-HIB Agents," <i>Tetrahedron Letters</i> 1989, pp. 6259-6262, Vol. 30, No. 46, Printed in Great Britain by Pergamon Press plc	
	14	VAN TILBURG, E.W., et al., "N <sup>6</sup> , 5'-Disubstituted Adenosine Derivatives as Partial Agonists for the Human Adenosine A <sub>3</sub> Receptor," <i>J. Med. Chem.</i> 1999, pp. 1393-1400, Vol. 42, No. 8	

RTA01/2156873v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.